Pirfenidone, a treatment agent for idiopathic pulmonary fibrosis, inhibits TAA-associated vascular inflammation and remodeling in wild type mice, but not in Aggf1+/- mice. This evidence concerns the gene AGGF1 and idiopathic pulmonary fibrosis.